Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

crizotinib

- PMLiVE

GSK’s anti-BCMA drug leads crowded CHMP recommendations

Ten new drugs receive positive recommendations for approval

Roche Basel Switzerland

Roche cites COVID-19 and biosimilars in Q2 decline

Pharmaceutical sales took a 4% hit in Swiss francs

- PMLiVE

US government pays $1.95bn for Pfizer/BioNTech’s COVID-19 vaccine

Initial order includes 100 million doses

- PMLiVE

EMA to support real-world monitoring of COVID-19 treatments/vaccines

New infrastructure will support real-world studies

- PMLiVE

UK agrees further COVID-19 vaccine deals with Pfizer/BioNTech, Valneva

Government has already agreed similar deal with AstraZeneca

- PMLiVE

Roche pays $775m upfront to access Blueprint’s RET programme

Expands on initial deal that is worth up to $1bn

- PMLiVE

Tecentriq misses the mark in advanced ovarian cancer

PD-L1 inhibitor failed to improved progression-free survival

- PMLiVE

FDA fast-tracks Pfizer/BioNTech’s COVID-19 vaccine candidates

Two investigational candidates granted accelerated review

- PMLiVE

Porter Novelli wins first Best Use of Data Visualisation Award at Communiqué 2020

The winning initiative for this new category was created by Pfizer Oncology

Roche Basel Switzerland

New data reinforces safety profile of Roche’s Hemlibra

Blockbuster haemophilia A treatment presents a strong challenge to rival drugs

- PMLiVE

IFPMA launches AMR Action Fund to tackle antimicrobial resistance

Pharma and health organisations unite to address public health threat

- PMLiVE

Pfizer jumps on early data from BioNTech-partnered COVID-19 vaccine study

Preliminary data demonstrates promising immunogenicity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links